osimertinib and Myositis

osimertinib has been researched along with Myositis* in 3 studies

Reviews

1 review(s) available for osimertinib and Myositis

ArticleYear
Myositis - A common but underreported adverse effect of osimertinib: Case series and review of the literature.
    Cancer treatment and research communications, 2020, Volume: 25

    Lung cancer is the second most common cancer in both men and women and the leading cause of cancer death worldwide. The development of novel tyrosine kinase inhibitors (TKIs) represented a paradigm shift in the management of lung cancer and has resulted in markedly prolonged survival. Osimertinib is a TKI that was fast-tracked by the United States Food and Drug Administration in 2015 and subsequently approved for the treatment of metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer. However, despite the generally favorable outcomes associated with osimertinib, rapid development and deployment of any new drug increases the risk of unforeseen adverse effects. Post-marketing surveillance studies therefore play an important role in further elucidating the risks and benefits of novel anti-neoplastic agents.. We describe four patients with non-small cell lung cancer who developed myositis after beginning treatment with osimertinib. In addition, we review the literature on osimertinib-associated myositis. Using PubMed, the following terms were searched and relevant citations assessed: creatine phosphokinase, myositis, osimertinib, rhabdomyolysis, osimertinib, and Tagrisso.. Thirty-eight patients were treated with osimertinib in our community clinic. Four with non-small cell lung cancer developed myositis after beginning treatment. The onset of symptoms and/or elevation of creatine phosphokinase occurred between two weeks and eleven months after osimertinib was initiated. Alternative causes for myositis were not identified. In two patients, myositis resolved within one month of withdrawing treatment. Two other patients continued osimertinib treatment with close monitoring.. Myositis is a serious and potentially underreported adverse effect of osimertinib. Previous studies suggest that osimertinib-associated myositis is rare, occurring in less than 1% of patients. However, myositis occurred in over 10% of patients treated with osimertinib in our clinic population. We suggest regular monitoring for myositis among patients being treated with osimertinib and dose-reduction or cessation of treatment if clinically indicated.

    Topics: Acrylamides; Adult; Aged; Aniline Compounds; Female; Humans; Male; Myositis; Protein Kinase Inhibitors

2020

Other Studies

2 other study(ies) available for osimertinib and Myositis

ArticleYear
EGFR-mutant lung adenocarcinoma associated with antisynthetase syndrome successfully treated with osimertinib.
    Thoracic cancer, 2021, Volume: 12, Issue:9

    Here, we report a rare case involving a 66-year-old man with epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma and antisynthetase syndrome (ASS) treated with osimertinib. The patient presented with respiratory failure and bilateral pulmonary opacities; he was diagnosed with ASS accompanied by interstitial lung disease (ILD), consistent with paraneoplastic syndrome. After steroid pulse therapy, osimertinib was administered for lung adenocarcinoma without ILD exacerbation. Osimertinib could therefore be a treatment option for EGFR-mutant lung cancer with paraneoplastic ILD.

    Topics: Acrylamides; Adenocarcinoma of Lung; Aged; Aniline Compounds; ErbB Receptors; Humans; Lung Neoplasms; Male; Myositis

2021
Myositis in a Patient with Advanced Lung Cancer Treated with Osimertinib.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2018, Volume: 13, Issue:8

    Topics: Acrylamides; Adenocarcinoma of Lung; Aged; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Humans; Lung Neoplasms; Male; Myositis

2018